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Currently, glycans are attracting attention from the scientiﬁc community as potential biomarkers or as posttranslational
modiﬁcations (PTMs) of therapeutic proteins. However, structural characterization of glycoproteins and glycopeptides remains
analytically challenging. Here, we report on the implementation of a novel acquisition strategy termed higher-energy collision
dissociation-accuratemass-product-dependentelectrontransferdissociation(HCD-PD-ETD)onahybridlineariontrap-orbitrap
mass spectrometer. This acquisition strategy uses the complementary fragmentations of ETD and HCD for glycopeptides analysis
in an intelligent fashion. Furthermore, the approach minimizes user input for optimizing instrumental parameters and enables
straightforward detection of glycopeptides. ETD spectra are only acquired when glycan oxonium ions from MS/MS HCD are
detected. The advantage of this approach is that it streamlines data analysis and improves dynamic range and duty cycle. Here,
we present the beneﬁts of HCD-PD-ETD relative to the traditional alternating HCD/ETD for a trainer set containing twelve-
protein mixture with two glycoproteins: human serotransferrin, ovalbumin and contaminations of two other: bovine alpha 1 acid
glycoprotein (bAGP) and bovine fetuin.
1.Introduction
Glycosylation is an important PTM that plays crucial roles
in various biochemical processes, ranging from mediation
of interactions between cells to deﬁning cellular identities
within complex tissues [1, 2]. In addition, glycan structures
are unique to the proteins which they are attached to and
to the site of attachment and, thus, play crucial roles in
controlling the activities of the proteins. Many glycans, also,
show disease-related expression level changes [3, 4]. For
example, changes in glycosylation patterns have been used
as a means to monitor progression of cancer [3–6]. In many
instances, it is essential to characterize the exact glycan
structure and site of glycosylation to better understand the
protein-mediated interaction that these glycans undergo.
Mass spectrometry (MS) has emerged as one of the most
powerful tools for proteomics due to its sensitivity of detec-
tion and its ability to analyze complex mixtures derived from
a variety of organisms and cell lines. However, structural
characterizationofglycoproteins/glycopeptidesremainsana-
lytically challenging due to the reliance on traditional acqui-
sition strategies and MS/MS fragmentation techniques.
Conventional proteomics has beneﬁtted tremendously
from collision-activated dissociation (CAD) due to the ease
of implementation of the technique on most commercial
mass spectrometers and the abundant peptide bond cleav-
ages that this technique generates, resulting in large number
of peptides and proteins identiﬁed. Unfortunately for glyco-
proteomics, CAD does not provide the necessary fragment
ions to thoroughly characterize intact glycopeptide struc-
tures [7]. Depending upon the mass spectrometers used,
CAD provides varying degrees of structural information. For
example, low-energy CAD on most mass spectrometers pre-
dominantly generates glycosidic bond cleavages with mini-
malfragmentationoccurringalongthepeptidebackbone[8–
11]. Additionally, cleavages also tend to occur between the
peptide-glycan bond, resulting in loss of information about
the site of glycosylation. The increase of collision energy can2 International Journal of Proteomics
result in more eﬃcient fragmentation of the peptide back-
bone, but this strategy can result in mixed MS/MS spectra
where both the glycan and peptide fragment ions are present
in the same spectra, complicating spectral interpretation
[12]. Regardless of whether high- or low-energy CAD is
employed, fragmentation of the peptide-glycan bond still
occurs limiting the ability to derive information about the
site of glycosylation. Majority of the current approaches
have foregone the strategy of examining intact glycopeptides
and have focused on obtaining partial information, such
as sequencing peptide backbone and identifying sites of
glycosylation. For example, the use of N-glycosidase F or A
(PNGase F/A) enzymes results in the removal of glycans and
conversionofasparagines,thesiteofglycosylationtoaspartic
acid.Thisconversionprocesscanthenbemonitoredbyhigh-
resolution MS due to a mass shift of 0.9840Da to identify
the site of glycosylation. Additionally, one can increase the
conﬁdence in the glycosylation site assignment by incorpo-
ration of stable isotope labeling by performing PNGaseF/A
digestion in the presence of H2O18. Such approach involves
the release of glycans by a deamidation reaction, and the
incorporation of H2O18 will lead to a mass shift of 2.9890Da
on the asparagine residue. But, studies have shown that these
types of chemical deamidations can occur spontaneously
during sample preparation for release of glycans in the
presence and absence of H2O18 leading to number of false
positives [13–17]. These issues underline the importance
of intact glycopeptides structural analysis, and only this
approach enables comprehensive structuralcharacterization.
Though CAD is limiting for glycopeptides analysis, alter-
native fragmentation techniques such as electron-capture
dissociation (ECD) [18]a n dE T D[ 19, 20]a r eb e t t e rs u i t e d
for glycopeptides analysis due to their nonergodic type of
dissociation. These dissociation techniques induce extensive
fragmentation of the peptide backbone enabling sequencing
of the peptide but preserving glycans on the peptide back-
bone allowing unambiguous assignment of the glycosylation
sites, thus providing complementary information to CAD.
Previously, several studies have demonstrated the utility
of combining CAD and ETD fragmentation for glycopep-
tides characterization [19–22]. For example, Catalina et al.
have performed detailed analysis of horse peroxidase using
alternating CID, ETD fragmentation [20]. We have shown
in the past the importance of combining ETD and CAD,
speciﬁcally HCD, for full structural characterization of
glycopeptides [22]. However, all of these studies have used
both types of fragmentation in an unselective fashion. Here,
we expand on this approach to report a novel acquisition
strategy termed HCD-PD-ETD that enables on the ﬂy iden-
tiﬁcation of glycopeptides and improves overall productivity
of glycopeptides analysis. In this approach, the LTQ Orbitrap
VelosacquiresHCDspectrainadata-dependentfashion.The
instrument identiﬁes glycan oxonium ions on the ﬂy in the
HCD spectra and triggers ETD spectra on the glycopeptides
precursor only. The advantage of this approach is that it
streamlines data analysis and improves dynamic range and
duty cycle. The beneﬁts of this novel acquisition strategy are
examined for a trainer set containing twelve-protein mixture
with two glycoproteins and contaminants of two others
and compared against the traditional alternating HCD/ETD
approach.
2.MaterialsandMethods
All protein and glycoprotein standards used in these experi-
mentswerepurchasedfromSigma-AldrichChemicalCo.(St.
Louis, MO, USA).
2.1. Protein Reduction, Alkylation, and Digestion. 100µgo f
equal molar twelve-protein mixture (lysozyme, glyceralde-
hyde-3-phosphate dehydrogenase, beta-casein, cytochrome
c, bovine serum albumin, ovalbumin, carbonic anhy-
drase, serotransferrin, alpha-lactalbumin, apo-myoglobulin,
bAGP, and bovine fetuin) was dissolved in 100µLo f
50mM TrisHCl, pH 8.6/0.1% SDS buﬀer. This was fol-
lowed by reduction with 5µL of 100mM tris(2-car-
boxyethyl)phosphine (TCEP) and incubation at 37◦Cf o r
30mins. The reduced twelve-protein mixture was then alky-
lated with 5µL of 375mM iodoacetic acid for 60 minutes,
protected from light. Upon alkylation, the twelve-protein
mixture was acetone precipitated over night at −30◦C. The
acetone-precipitated twelve-protein mixture was dissolved in
100µL of 100mM triethyl ammonium bicarbonate (TEAB)
and digested at 37◦C for 4 hours with 2.5µg of trypsin (1:40
enzyme:protein ratio).
2.2. TMT Labeling. Isobaric labeling was accomplished with
TMT6 reagent (Thermo Scientiﬁc, Rockford, IL, USA) per
manufacturer’s suggestion. Brieﬂy, the reagent was dissolved
in 41µL of anhydrous acetonitrile and added to 100µg
of tryptically digested twelve-protein mixture. The sample
was then incubated at room temperature for 1 hour and
quenchedwiththeadditionof8µLof5%hydroxylamineand
concentrated to 10µL using Speed Vac (Thermo Scientiﬁc,
Waltham, MA, USA).
2.3. LC/MS. A Thermo Scientiﬁc EASY-nLC nano-HPLC
systemand Michrom MagicC18 spraytip 15cm ×75µmi.d.
column (Auburn, CA) were used. Gradient elution was per-
formed from 5 to 45% ACN in 0.1% formic acid over 60min
at a ﬂow rate of 300nL/min. The samples were analyzed with
a Thermo Scientiﬁc LTQ Orbitrap Velos hybrid mass spec-
trometer with ETD. The following MS and MS/MS settings
were used: FT: MSn AGC Target = 5e4; MS/MS = 1µscans,
200ms max ion time; MS = 400–2000m/z, 60000 resolution
at m/z 400, MS Target = 1e6; MS/MS = Top 10 data-
dependent acquisition HCD product-dependent acquisition
iontrapETD(Figure 1),dynamicexclusion =repeat count 1,
Duration30sec,exclusionduration90sec;HCDParameters:
collision energy = 35%; resolution 7500. MSn target ion
trap = 1e4, 3µscans, 150ms max ion time; ETD anion AGC
target = 2e5, and charge-dependent ETD reaction time was
used.
2.4. Data Processing. The prototype GlycoMaster (Bioinfor-
matics Solution, Waterloo, ON, Canada) software was used
for intact glycopeptides analysis. Searches were performed
using a 5ppm precursor ion tolerance and 0.8Da ETDInternational Journal of Proteomics 3
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Figure 1: Schematic representation of HCD-PD-ETD acquisition method.
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Figure 3:LC-MSiontrapETDspectrumofbAGPN-linkedglycopeptideT103–109precursorat(a)m/z1165.823(3+)and(b)m/z1148.174
(3+).
tolerance and 0.02Da HCD tolerance, while allowing up to
one missed cleavage. For peptide searches, carboxymethyla-
tion of cysteine residues (+58.005478Da) was set as static
modiﬁcation. TMT6 tag on lysine residues and peptide N
termini (+229.16293Da) were set as variable modiﬁcation.
For glycan identiﬁcation, the following possible monosac-
charide combinations were searched: Hexose, HexNAc,
Deoxyhexose, Neu5Gc, and Neu5Ac. Both O- and N-linked
glycosylationswereconsideredwithH,Na,andKaspotential
adducts. To minimize on false hits for site of glycosylation,
GlycoMaster considered N-linked glycosylation to occur at
the amide residue of asparagine in a consensus sequence of
Asn-Xaa-Ser/Thr (X can be any amino acid except proline)
and O-linked glycosylation to occur at serine or threonine
residues. All results were manually validated.
3. Results and Discussion
Current MS/MS acquisition strategies for glycopeptides
analysisrelyonacquiringMS/MSspectraforallprecursorsin
a mass spectrum regardless of whether the precursor belongs
to a glycopeptide. The resultant spectra are then interrogated
after acquisition for characteristic glycan oxonium ions
(which are dominant in the MS/MS CAD spectra) for
detection of glycopeptides, and the corresponding spectra
are then used in the identiﬁcation [19–25]. The limitationInternational Journal of Proteomics 5
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Figure 4: LC-MS ion trap ETD spectrum of bovine fetuin N-linked glycopeptide T72–103 precursor at m/z 1219.950 (5+).
of this approach is that both data acquisition and data
interrogation are not performed as eﬃciently as possible. By
triggering MS/MS spectra on all precursors, both duty cycle
and dynamic range of analysis are decreased. Furthermore,
postacquisition extraction of glycan oxonium ions requires
additional tools to ascertain information about detected
glycopeptides: their charge state and m/z. Further adding to
the ineﬃciency of the current MS/MS acquisition strategies
is that if a mass spectrometer with nominal mass accuracy
is used, then more than one glycan oxonium ion must be
extracted to minimize on false positives due to near mass
isobaric ions [26]. However, in our approach, we employ
HCD to generate glycan oxonium ions. The advantage of
using HCD is that the generated fragment ions are measured
within the orbitrap mass analyzer with high resolution and
mass accuracy (HR/AM) allowing for unambiguous assign-
ment of glycan oxonium ions [23]. Using orbitrap detection
to our advantage, we have implanted a novel instrumental
control within the hybrid linear ion trap-orbitrap mass
spectrometer termed HCD-PD-ETD (Figure 1). This instru-
mental control enables the mass spectrometer to identify
glycopeptides on the ﬂy and acquire data in an intelligent
fashion. In this approach, we specify certain glycan oxonium
ions for the instruments to monitor within the HCD
spectrum (up to ten diﬀerent product ions can be speciﬁed).
We typically use m/z 204.0864 HexNAc oxonium ion and
its fragments 168.0653 and 138.0550 as diagnostic ions
to be monitored in HCD fragmentation, and, by method
deﬁnition, the monitored ions should be in the top 20–30
most intense fragment ions. However, if glycopeptides of
interest do not contain terminal HexNAc, other diagnostic
oxonium/product ions can be selected and collision energy
optimized accordingly. The hybrid linear ion trap-orbitrap
mass spectrometer equipped with ETD then acquires HCD
spectra in a data-dependent fashion. Each HCD spectrum is
interrogated by the instrument on the ﬂy for the presence
of diagnostic glycan oxonium (product) ions at ppm mass
accuracy. If a diagnostic glycan oxonium (product) ion is
detected, an ETD spectrum for the glycopeptide precur-
sor is acquired. It should be noted that we can specify
mass accuracy as low as 5ppm for high selectivity. This
novel acquisition strategy provides numerous advantages.
Primarily, it increases overall productivity for MS analysis
of glycopeptides by acquiring ETD spectra only when a
glycopeptide is detected, enabling improvements in both
duty cycle and dynamic range of analysis. Additionally, this
approach improves data analysis by decreasing the rate of
false positives, the overall ﬁle size, and the number of ETD
spectra that are extrapolated to characterize glycopeptides.
To demonstrate the advantage of our novel acquisition
strategy,weselectedatwelve-protein mixturecontainingtwo
glycoproteins: human serotransferrin and ovalbumin and
contaminants of two others: bAGP and bovine fetuin. The
mixture was digested with trypsin and analyzed by the tradi-
tional alternating HCD/ETD approach and the novel HCD-
PD-ETD approach. Enrichment steps were avoided prior to
analysis to ensure that the glycopeptides would be very low
in abundances; this gave us the opportunity to evaluate the
dynamic range of analysis for both acquisition strategies.
Of the two, only HCD-PD-ETD approach identiﬁed gly-
copeptides from the contaminant glycoproteins (bAGP and
bovine fetuin) present in the sample (Figure 2). While the
HCD/ETDacquisitionstrategyidentiﬁednumerouspeptides
and expected glycopeptides (eluted at 34, 40, and 48min6 International Journal of Proteomics
Table 1: List of identiﬁed contaminant glycopeptides and corresponding glycoforms from the 12-protein mixture digest by HCD-PD-ETD.
Peptide sequence Glycan no. Glycan composition
T103–109 QNGTLSK(bAGP) 1d H e x H e x 4HexNAc4Neu5Gc2
2H e x 5HexNAc4Neu5Gc2
T72–103 RPTGEVYDIEDTLETTCHVLDPTPLANCSVR (bovine fetuin)
3H e x 6HexNAc6
4H e x 4HexNAc6Neu5Ac
5H e x 5HexNAc5Neu5Ac
as shown in Figure 2 for HCD-PD-ETD approach) from
serotransferrin and ovalbumin, it was unable to identify
glycopeptides from the contaminant glycoproteins. Manual
inspection of the RAW data conﬁrmed this, as precursors
associated with the contaminant glycopeptides were not
targeted for MS/MS by HCD or ETD in the alternating
approach. Analysis of the HCD-PD-ETD data revealed the
identiﬁcation of glycopeptides from expected glycoproteins
and the contaminant glycoproteins. Identiﬁed minor gly-
copeptides from the contaminant glycoproteins by HCD-
PD-ETD acquisition method are presented in Table 1,a n d
representative ETD MS/MS spectra used in identiﬁcation are
shown in Figures 3 and 4. Because HCD-PD-ETD acqui-
sition strategy did not waste time acquiring ETD data for
nonglycosylated peptides, it was able to dig deeper into the
sample and identify this low abundant glycopeptides that the
alternating HCD/ETD acquisition strategy could not target.
In summary, we have been able to develop a novel acqui-
sition strategy that minimizes some of the pain points asso-
ciated with glycopeptide analysis. By combining the com-
plementary information provided by HCD and ETD in an
intelligent acquisition control, the overall productivity of
g l y c o p e p t i d e sa n a l y s i si si m p r o v e d .
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